A Study of Prexasertib (LY2606368) in Participants With Advanced Cancer

NCT02778126 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

6

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced Cancer

Interventions

DRUG: [¹⁴C]Prexasertib
DRUG: Prexasertib

Sponsor

Eli Lilly and Company